secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001434647-25-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Q3 net loss narrows to $0.5M; revenue jumps to $26.1M on MIPLYFFA sales
-----------------------------------------------------------------------------

- Q3 net revenue $26.1M (vs $3.7M YoY), with MIPLYFFA contributing $22.4M.
- Net loss $(0.5)M or $(0.01) per share vs $(33.2)M or $(0.69) per share in Q3 2024.
- MIPLYFFA prescription enrollment forms total 137 since launch; market access 66% of covered lives.
- Cash and securities $230.4M as of Sep 30, 2025; company believes sufficient to fund operations.
- Arimoclomol EMA application validated under review; celiprolol Phase 3 trial enrolled 44 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143464725000009/0001434647-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143464725000009/zvra-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001434647-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer